There has been noteworthy progress in the oligonucleotide therapeutics field over the past 30 years, beginning with antisense oligonucleotides (ASOs) and aptamers and followed about 15 years ago by siRNAs. Recent innovations in gene editing field is driving the need for oligonucleotides characterization.
Run time: 49:31 mins
Webinar "Simplifying Oligonucleotide Drug Development Workflows with Mass Spectrometry"
Video Credit: Bruker Life Sciences Mass Spectrometry